{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:08:27Z","timestamp":1778882907517,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["2022-N-01"],"award-info":[{"award-number":["2022-N-01"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ijcha.2024.101571","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T18:15:44Z","timestamp":1734372944000},"page":"101571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Bibliometric analysis of levosimendan"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5543-4096","authenticated-orcid":false,"given":"Xian-Shu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Tai","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ijcha.2024.101571_b0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10557-013-6485-6","article-title":"Renal effects of levosimendan: a consensus report","volume":"27","author":"Yilmaz","year":"2013","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"1","key":"10.1016\/j.ijcha.2024.101571_b0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FJC.0000000000000859","article-title":"Levosimendan efficacy and safety: 20 Years of SIMDAX in clinical use","volume":"76","author":"Papp","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"16","key":"10.1016\/j.ijcha.2024.101571_b0015","article-title":"Levosimendan in Europe and China: an appraisal of evidence and context","volume":"8","author":"Kong","year":"2021","journal-title":"Eur Cardiol."},{"issue":"1","key":"10.1016\/j.ijcha.2024.101571_b0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/s13054-019-2674-4","article-title":"Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper","volume":"23","author":"Cholley","year":"2019","journal-title":"Crit. Care"},{"key":"10.1016\/j.ijcha.2024.101571_b0025","article-title":"Multiorgan drug action of levosimendan in critical illnesses","volume":"19","author":"Pan","year":"2019","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.ijcha.2024.101571_b0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(97)01108-4","article-title":"Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes","volume":"333","author":"Yokoshiki","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ijcha.2024.101571_b0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0014-2999(01)01350-4","article-title":"Levosimendan is a mitochondrial K(ATP) channel opener","volume":"428","author":"Kopustinskiene","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ijcha.2024.101571_b0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1074248406289286","article-title":"Effect of levosimendan and milrinone on regional myocardial ischemia\/reperfusion-induced arrhythmias in dogs","volume":"11","author":"Papp","year":"2006","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.ijcha.2024.101571_b0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/bjp.2008.52","article-title":"A role for the RISK pathway and KATP channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart","volume":"154","author":"du Toit","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijcha.2024.101571_b0050","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/bja\/aen367","article-title":"Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery","volume":"102","author":"Tritapepe","year":"2009","journal-title":"Br. J. Anaesth."},{"issue":"2","key":"10.1016\/j.ijcha.2024.101571_b0055","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1160\/TH14-06-0549","article-title":"Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro","volume":"113","author":"Krychtiuk","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.ijcha.2024.101571_b0060","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1097\/CCM.0000000000001269","article-title":"Anti-inflammatory profile of levosimendan in cecal ligation-induced septic mice and in lipopolysaccharide-stimulated macrophages","volume":"43","author":"Wang","year":"2015","journal-title":"Crit. Care Med."},{"issue":"1","key":"10.1016\/j.ijcha.2024.101571_b0065","doi-asserted-by":"crossref","first-page":"9704","DOI":"10.1038\/srep09704","article-title":"Levosimendan displays anti-inflammatory effects and decreases MPO bioavailability in patients with severe heart failure","volume":"5","author":"Adam","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ijcha.2024.101571_b0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000455950","article-title":"Levosimendan pretreatment inhibits myocardial apoptosis in swine after coronary microembolization","volume":"41","author":"Wang","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ijcha.2024.101571_b0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fphys.2012.00017","article-title":"Intracoronary levosimendan during ischemia prevents myocardial apoptosis","volume":"3","author":"Malmberg","year":"2012","journal-title":"Front. Physiol."},{"issue":"7","key":"10.1016\/j.ijcha.2024.101571_b0080","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jcma.2016.12.008","article-title":"Levosimendan mitigates coagulopathy and organ dysfunction in rats with endotoxemia","volume":"80","author":"Huang","year":"2017","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/j.ijcha.2024.101571_b0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.thromres.2017.10.001","article-title":"Impact of levosimendan on platelet function","volume":"159","author":"Sikora","year":"2017","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.ijcha.2024.101571_b0090","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/09537104.2012.726755","article-title":"Levosimendan\u2019s effect on platelet function in a rat sepsis model","volume":"24","author":"Bent","year":"2013","journal-title":"Platelets"},{"key":"10.1016\/j.ijcha.2024.101571_b0095","doi-asserted-by":"crossref","unstructured":"Bourgoin P, Lecomte J, Oualha M, Berthomieu L, Pereira T, Davril E, Lamoureux F, Joram N, Chenouard A, Duflot T. Population Pharmacokinetics of levosimendan and its Metabolites in Critically Ill Neonates and Children Supported or Not by Extracorporeal Membrane Oxygenation. Clin Pharmacokinet. 2023 Feb;62(2):335-348. doi: 10.1007\/s40262-022-01199-y. Epub 2023 Jan 11. Erratum in: Clin Pharmacokinet. 2023 Feb 8;: PMID: 36631687.","DOI":"10.1007\/s40262-022-01199-y"},{"issue":"4","key":"10.1016\/j.ijcha.2024.101571_b0100","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/0091270007313390","article-title":"Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment","volume":"48","author":"Puttonen","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcha.2024.101571_b0105","unstructured":"Pritchard A.Statisticalbibliographyorbibliometrics?[J].Documentation,1969,25(4):348-349."},{"issue":"6","key":"10.1016\/j.ijcha.2024.101571_b0110","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/phar.1586","article-title":"A descriptive and historical review of bibliometrics with applications to medical sciences","volume":"35","author":"Thompson","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijcha.2024.101571_b0115","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"10.1016\/j.ijcha.2024.101571_b0120","first-page":"1","article-title":"detecting and visualizing emerging trends and transient patterns in scientific literature","author":"Chen","year":"2003","journal-title":"J. Assoc. Inf. Sci. Technol."},{"issue":"Suppl 1","key":"10.1016\/j.ijcha.2024.101571_b0125","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1073\/pnas.0307513100","article-title":"Searching for intellectual turning points: progressive knowledge domain visualization","volume":"101","author":"Chen","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.ijcha.2024.101571_b0130","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/asi.20317","article-title":"Citespace II: detecting and visualizing emerging trends and transient patterns in scientifific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J. Am. Soc. Inf. Sci."},{"issue":"9328","key":"10.1016\/j.ijcha.2024.101571_b0135","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ijcha.2024.101571_b0140","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","article-title":"RUSSLAN study investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)","volume":"23","author":"Moiseyev","year":"2002","journal-title":"Eur. Heart J."},{"issue":"17","key":"10.1016\/j.ijcha.2024.101571_b0145","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"SURVIVE investigators. Ievosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ijcha.2024.101571_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/S0021-9258(19)61945-9","volume":"269","author":"Pollesello","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"21","key":"10.1016\/j.ijcha.2024.101571_b0155","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1616218","article-title":"levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery","volume":"376","author":"Mehta","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ijcha.2024.101571_b0160","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1616325","article-title":"Levosimendan for hemodynamic support after cardiac surgery","volume":"376","author":"Landoni","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ijcha.2024.101571_b0165","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.ijcha.2024.101571_b0170","doi-asserted-by":"crossref","first-page":"R140","DOI":"10.1186\/cc10263","article-title":"Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials","volume":"15","author":"Maharaj","year":"2011","journal-title":"Crit. Care"},{"issue":"3","key":"10.1016\/j.ijcha.2024.101571_b0175","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1053\/j.ajkd.2015.09.015","article-title":"Levosimendan for prevention of acute kidney injury after cardiac surgery: a meta-analysis of randomized controlled trials","volume":"67","author":"Zhou","year":"2016","journal-title":"Am. J. Kidney Dis."},{"issue":"12","key":"10.1016\/j.ijcha.2024.101571_b0180","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ejheart.2008.09.006","article-title":"Oral levosimendan in patients with severe chronic heart failure --the PERSIST study","volume":"10","author":"Nieminen","year":"2008","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcha.2024.101571_b0181","first-page":"317","article-title":"The frequency distribution of scientific productivity","volume":"16","author":"Lotka","year":"1926","journal-title":"J. Washington Acad. Sci."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724002379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724002379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:18:34Z","timestamp":1778879914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906724002379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":37,"alternative-id":["S2352906724002379"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101571","relation":{},"ISSN":["2352-9067"],"issn-type":[{"value":"2352-9067","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bibliometric analysis of levosimendan","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101571","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101571"}}